Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Laura Laine Herborg , Line Nederby , Eigil Kjeldsen , Kirsten Grønbæk , Peter Hokland , Maria Hansen , Marcus Celik Hansen , Anne Stidsholt Roug Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven leukemogenesis in a patient with multiple TET2 mutations and JAK2 V617F mutated chronic myeloproliferative neoplasm. The del(7q) emerged in the accelerated phase of disease, which was preceded by a...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Anne-Louise Latif , Grant McQuaker , Anne Parker , Andrew Clark , Mhairi Copland Most patients now receiving a haematopoietic stem cell transplant (HSCT) for chronic myeloid leukaemia (CML) have been treated with first and second line TKIs pre-HSCT, raising concerns that these patients will have more resistant disease and accumulated greater toxicity from sequential lines of therapy, potentially compromising their outcome. We outline a series of 9 patients treated with imatinib then second generation TKIs for CML followed by HSCT...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Antonella Poloni , Benedetta Costantini , Marianna Mariani , Pietro Leoni Myelodysplastic syndromes are heterogeneous myeloid neoplasms ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia. Here we report a 51-year-old woman with depression and severe obesity who was diagnosed with an International Prognostic Scoring System low-risk myelodysplastic syndrome, presenting mainly with thrombocytopenia, treated with escalating dose of valproic acid as a single agent. After two ...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Treatment of acute erythroleukemia with Azacitidine: A case series
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Francesca Pierdomenico , Antonio Almeida Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia (AML) often associated with a poor prognosis. It is more frequent in elderly patients, limiting the use aggressive therapies. Azacitidine is a hypomethylating agent with recognized efficacy in high risk myelodysplasia and AML in the elderly. Here we report 5 cases of AEL treated with Azacitidine. The cohort included 4 men and 1 woman, median age 70. One patient had been refractory to intensive chemotherapy, the others receiv...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in patients with KPS≥90 and lower in recipient/donor CMV+/− vs. other combinations. FluCy has low TRM and is curative in about 20% of high-risk patients. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 1 Author(s): Daisuke Okamura , Akira Matsuda , Maho Ishikawa , Tomoya Maeda , Ken Tanae , Mika Kohri , Naoki Takahashi , Nobutaka Kawai , Norio Asou , Masami Bessho Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75mg/m2/daily subcutaneously for 7days every 28days. Hematologic ...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Intravascular large B cell lymphoma
We present an illustrative case of intravascular B cell lymphoma suspected by the presence of a very small monoclonal B cell population identified by immunophenotype and polymerase chain reaction in bone marrow. The diagnosis was confirmed by skin biopsy. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia
Conclusions No relationship was found between baseline WBCs or hepatic function and response. Higher baseline creatinine in nonresponders may not be clinically relevant. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Acute renal failure and normal blood count: A rare presentation of T-cell acute lymphoblastic leukemia
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 1 Author(s): Peter H. Asdahl , Linda F. Warner , Knud Bendix , Henrik Hasle A 10-year-old boy presented with headache and visual disturbance. During work-up in hospital he developed acute renal failure with a maximum creatinine level of 534μmol/l. Complete blood count was normal. Kidney and bone marrow biopsy both showed massive infiltration of lymphoblasts of T-cell linage. Renal function normalized rapidly on prednisolone therapy. Kidney involvement in acute lymphoblastic leukemia is uncommon and renal failure due to leukemic infiltration i...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H
We report on a 55-year-old female patient with acute MCL diagnosed in May 2012. The disease was characterized by a rapid increase in white blood cells and mast cells (MC) in the peripheral blood, and a rapid increase of serum tryptase levels. The KIT D816H mutation was detected in the blood and bone marrow (BM). Induction chemotherapy with high-dose ARA-C and fludarabine (FLAG) was administered. Unexpectedly, the patient entered a hematologic remission with almost complete disappearance of neoplastic MC and a decrease of serum tryptase levels to normal range after 2 cycles of FLAG. Consecutively, the patient was prepared f...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Extreme hyperleukocytosis in a pediatric T-ALL patient with a rare translocation, t(7;19)(q35;p13), and submicroscopic deletions at 4q25, 7q33 and 10q23
We report on a 2-year-old T-ALL patient presenting with a very short history of constipation and extreme hyperleukocytosis (WBC 882×109/L). In her leukemic cells we detected the very rare translocation t(7;19)(q35;p13) and LYL1 overexpression. Additionally, we detected submicroscopic deletions at 4q25, 7q33 and 10q23 by oligo-aCGH analysis. We suggest that LYL1 overexpression contributed to the leukemic state and propose that the observed microdeletions may have influenced to the rapid disease progression. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Prevalence of human endogenous retroviral element associates with Hodgkin's lymphoma incidence rates
Publication date: 2014 Source:Leukemia Research Reports, Volume 3, Issue 1 Author(s): Wee Hong Woo , Liang Shen , Sai Mun Leong , Evelyn Siew-Chuan Koay Human endogenous retrovirus-H (HERV-H) is implicated in leukaemias and lymphomas, but the precise molecular mechanism underlying HERV-mediated carcinogenesis remains unknown. We determined the prevalence of HERV-H in a cross-section of the Singapore population and explored the relationship between HERV-H positivity and incidence rates for Hodgkin's lymphoma in three major ethnic groups of Singapore. We observed that Malays were 1.11 times likely (95% CI=1.05–1.17...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
An unusual case of splenomegaly and increased lactate dehydrogenase heralding acute myeloid leukemia with eosinophilia and RUNX1–MECOM fusion transcripts
We report the first case of acute myeloid leukemia (AML) with RUNX1–MECOM fusion transcripts, showing marked eosinophilia. A 63-year old man admitted in August 2013, had previously been observed in April 2013, because of persisting homogeneous splenomegaly and increased LDH, which were initially attributed to both minor β-thalassemia and previous acute myocardial infarction. However, based upon the retrospective analysis of clinical features combined with the documentation of both JAK2 V617F and c-KIT D816V mutations at AML diagnosis, an aggressive leukemic transformation with eosinophilia of a previously unrecognized m...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
